Lipogems Raises Funds for Knee Osteoarthritis Studies

Lipogems raised €12.5 million (~USD $13.2 million) in growth capital in 2022 to support the recent FDA-approved Investigational Device Exemption studies for a separate and specific indication in knee osteoarthritis (OA).

Lipogems' minimally invasive procedure is performed one time in a sterile setting (outpatient or operating room) in...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us